UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d)
of
The Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported) April
16, 2007
BODISEN
BIOTECH, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-32616
|
98-0381367
|
|
(State
or other Jurisdiction of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification
No.)
|
North
Part of Xinquia Road, Yang Ling Agricultural High-Tech
People's
Republic of China 712100
(Address
of Principal Executive Offices
86-29-87074957
(Registrant’s
Telephone Number, Including Area Code
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02. Results
of Operations and Financial Condition.
(a) On
April
16, 2007, Bodisen issued a press release reporting its preliminary financial
results for its year ended December 31, 2006. A copy of Bodisen’s press
release is attached hereto as Exhibit 99.1 and is incorporated herein by
reference.
The
information contained herein and the exhibit hereto are being furnished and
shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, and shall not be deemed incorporated by reference in
any
filing with the Securities and Exchange Commission under the Securities Exchange
Act of 1934 or the Securities Act of 1933, whether made before or after the
date
hereof and irrespective of any general incorporation language in any filings.
Item
9.01 Financial
Statements and Exhibits
|
(d)
|
|
Exhibits |
|
|
| |
|
|
|
|
| |
|
Exhibit No. |
|
Description |
| |
|
|
|
|
| |
|
99.1 |
|
Press Release dated April 16,
2007 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
| |
|
|
| |
BODISEN
BIOTECH, INC. |
| |
(Registrant) |
|
|
|
| Date: Date:
April
15, 2007 |
By: |
/s/
Bo
Chen
|
| |
Bo Chen |
| |
Chairman,
Chief Executive Officer and President
|